Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

Expert Rev Resp Med. 2012;6(3):255-265. The acute effect of the combination oral sildenafil and inhaled treprostinil has also been assessed. Fifty patients with pulmonary hypertension of varying ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Six-minute walk distance improved over 52 weeks with ...

Clinical Trial Results in Pulmonary Medicine Advance Outcomes session, TETON-1 evaluated inhaled treprostinil in patients ...

Please provide your email address to receive an email when new articles are posted on . United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of ...

Inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD). The study used a real-world database, comparing iTRE initiators ...

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Further, open label extension data published in 2023 showed ...

Treprostinil currently carries indications for improving exercise ability in pulmonary arterial hypertension and pulmonary ...

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

Recently published Pulmonary Arterial Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, pulmonary arterial hypertension emerging drugs, market ...

The search for an effective oral prostanoid is ongoing. Initial encouraging results were seen for oral beraprost, with participants in the first placebo-controlled trial seeing improvements in 6MWD ...

Inhaled iloprost was recently approved as a treatment for severe pulmonary arterial hypertension in Europe, Australia and the US, but inhalation sessions of up to approximately 2 h per day are ...